Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Terminated
Trial end date:
2016-03-18
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy (based on mean change in Cohen-Mansfield Agitation Inventory [CMAI]
total score from baseline as the primary efficacy variable), dose-response, and safety of
aripiprazole at 2, 3, and 6 mg/day in comparison with placebo in patients with agitation
associated with Alzheimer's type dementia